Background In human leishmaniasis Th1/Th2 dichotomy similar to murine model is not clearly defined and surrogate marker(s) of protection is not yet known. In this study, Th1/Th2 cytokines (IL-5, IL-10, IL-13 and IFN-γ) profile induced by purified CD4+/CD8+ T cells in response to Leishmania antigens were assessed at transcript and protein levels in 14 volunteers with a history of self-healing cutaneous leishmaniasis (HCL) and compared with 18 healthy control volunteers. Methodology/Principal Findings CD4+/CD8+/CD14+ cells were purified from peripheral blood using magnetic beads; CD4+/CD8+ T cells were co-cultured with autologous CD14+ monocytes in the presence of soluble Leishmania antigens (SLA). Stimulation of either CD4+ T cells or CD8+ T cells of HCL volunteers with SLA induced a significantly (P<0.05) higher IFN-γ production compared with the cells of controls. Upregulation of IFN-γ gene expression in CD4+ cells (P<0.001) and CD8+ cells (P = 0.006) of HCL volunteers was significantly more than that of controls. Significantly (P<0.05) higher fold-expression of IFN-γ gene was seen in CD4+ cells than in CD8+ cells. In HCL volunteers a significantly (P = 0.014) higher number of CD4+ cells were positive for intracellular IFN-γ production than CD8+ cells. Conclusions/Significance Collectively, the volunteers have shown maintenance of specific long-term immune responses characterized by a strong reaction to leishmanin skin test and IFN-γ production. The dominant IFN-γ response was the result of expansion of both CD4+ and CD8+ T cells. The results suggested that immune response in protected individuals with a history of zoonotic cutaneous leishmaniasis (ZCL) due to L. major is mediated not only through the expansion of antigen-specific IFN-γ producing CD4+ Th1 cells, but also through IFN-γ producing CD8+ T cells.
References
[1]
Stuart K, Brun R, Croft S, Fairlamb A, Gurtler RE, et al. (2008) Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 118: 1301–1310. doi: 10.1172/JCI33945
Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. ClinMicrobiolRev 19: 111–126. doi: 10.1128/cmr.19.1.111-126.2006
[4]
Modabber F, Buffet PA, Torreele E, Milon G, Croft SL (2007) Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006. Kinetoplastid Biol Dis 6: 3. doi: 10.1186/1475-9292-6-3
[5]
Khatami A, Firooz A, Gorouhi F, Dowlati Y (2007) Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57: 335–329. doi: 10.1016/j.jaad.2007.01.016
[6]
Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F (2006) Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123: 423–438.
[7]
Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, et al. (2009) Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27: 4747–4753. doi: 10.1016/j.vaccine.2009.05.084
[8]
Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner KD Jr (1987) Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol 138: 744–749.
[9]
Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845–858. doi: 10.1038/nri933
[10]
Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A (2000) Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 68: 1760–1764. doi: 10.1128/IAI.68.4.1760-1764.2000
[11]
Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, et al. (2009) Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. Hum Immunol 70: 383–390. doi: 10.1016/j.humimm.2009.01.007
[12]
Habibi GR, Khamesipour A, McMaster WR, Mahboudi F (2001) Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol 54: 414–420. doi: 10.1046/j.1365-3083.2001.00990.x
[13]
Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, et al. (2003) Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 134: 303–308. doi: 10.1046/j.1365-2249.2003.02299.x
[14]
Nateghi Rostami M, Keshavarz Valian H, Eskandari SE, Miramin Mohammadi A, Shahrestani ST, et al. (2010) Differential in vitro CD4 +/CD8+ T cell response to live vs. killed Leishmania major Parasite Immunol 32: 101–110. doi: 10.1111/j.1365-3024.2009.01164.x
[15]
Nateghi Rostami M, Khamesipour A, Eskandari SE, Miramin Mohammadi A, Sarraf-Nejad A, et al. (2008) Flow cytometric analysis of Leishmania reactive CD4+/CD8+ lymphocyte proliferation in cutaneous leishmaniasis. Iranian J Parasitol 3: 9–18.
[16]
Ruiz JH, Becker I (2007) CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 29: 671–678. doi: 10.1111/j.1365-3024.2007.00991.x
[17]
Caceres-Dittmar G, Tapia FJ, Sanchez MA, Yamamura M, Uyemura K, et al. (1993) Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 91: 500–505. doi: 10.1111/j.1365-2249.1993.tb05931.x
[18]
Castes M, Cabrera M, Trujillo D, Convit J (1988) T-cell subpopulations, expression of interleukin-2 receptor, and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis. J Clin Microbiol 26: 1207–1213.
[19]
Rogers KA, Titus RG (2004) The human cytokine response to Leishmania major early after exposure to the parasite in vitro. J Parasitol 90: 557–563. doi: 10.1645/GE-3317
[20]
Parker SJ, Roberts CW, Alexander J (1991) CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol 84: 207–212. doi: 10.1111/j.1365-2249.1991.tb08150.x
[21]
Suzuki Y (2002) Immunopathogenesis of cerebral toxoplasmosis. JInfectDis 186: Suppl 2S234–S240. doi: 10.1086/344276
[22]
Wang X, Michie SA, Xu B, Suzuki Y (2007) Importance of IFN-gamma-mediated expression of endothelial VCAM-1 on recruitment of CD8+ T cells into the brain during chronic infection with Toxoplasma gondii. J Interferon Cytokine Res 27: 329–338. doi: 10.1089/jir.2006.0154
[23]
Hafalla JC, Cockburn IA, Zavala F (2006) Protective and pathogenic roles of CD8+ T cells during malaria infection. Parasite Immunol 28: 15–24. doi: 10.1111/j.1365-3024.2006.00777.x
[24]
Miyakoda M, Kimura D, Yuda M, Chinzei Y, Shibata Y, et al. (2008) Malaria-specific and nonspecific activation of CD8+ T cells during blood stage of Plasmodium berghei infection. J Immunol 181: 1420–1428.
[25]
McMichael A, Hanke T (2002) The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2: 283–291. doi: 10.1038/nri779
[26]
McMichael AJ, Ogg G, Wilson J, Callan M, Hambleton S, et al. (2000) Memory CD8+ T cells in HIV infection. Philos Trans R Soc Lond B Biol Sci 355: 363–367. doi: 10.1098/rstb.2000.0575
[27]
Papagno L, Spina CA, Marchant A, Salio M, Rufer N, et al. (2004) Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2: E20. doi: 10.1371/journal.pbio.0020020
[28]
Gulzar N, Copeland KF (2004) CD8+ T-cells: function and response to HIV infection. Curr HIV Res 2: 23–37. doi: 10.2174/1570162043485077
[29]
Lara-Tejero M, Pamer EG (2004) T cell responses to Listeria monocytogenes. Curr Opin Microbiol 7: 45–50. doi: 10.1016/j.mib.2003.12.002
[30]
Herath S, Kropf P, Muller I (2003) Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells. Parasite Immunol 25: 559–567. doi: 10.1111/j.0141-9838.2004.00668.x
[31]
Muller I, Kropf P, Etges RJ, Louis JA (1993) Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun 61: 3730–3738.
[32]
Tsagozis P, Karagouni E, Dotsika E (2003) CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol 25: 569–579. doi: 10.1111/j.0141-9838.2004.00672.x
[33]
Uzonna JE, Joyce KL, Scott P (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. J Exp Med 199: 1559–1566. doi: 10.1084/jem.20040172
[34]
Bittar RC, Nogueira RS, Vieira-Goncalves R, Pinho-Ribeiro V, Mattos MS, et al. (2007) T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz 102: 625–630. doi: 10.1590/S0074-02762007005000069
[35]
Coutinho SG, Da-Cruz AM, Bertho AL, Santiago MA, De-Luca P (1998) Immunologic patterns associated with cure in human American cutaneous leishmaniasis. BrazJ Med Biol Res 31: 139–142. doi: 10.1590/S0100-879X1998000100019
[36]
Da-Cruz AM, Bertho AL, Oliveira-Neto MP, Coutinho SG (2005) Flow cytometric analysis of cellular infiltrate from American tegumentary leishmaniasis lesions. Br J Dermatol 153: 537–543. doi: 10.1111/j.1365-2133.2005.06647.x
[37]
Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, et al. (2002) T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diagn Lab Immunol 9: 251–256. doi: 10.1128/cdli.9.2.251-256.2002
[38]
Nateghi Rostami M, Keshavarz H, Khamesipour A (2010) Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae. Trop Biomed 27: 89–102.
[39]
Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988) CD4+ T cell subsets in experimental cutaneous leishmaniasis. Mem Inst Oswaldo Cruz 83: Suppl 1256–259. doi: 10.1590/S0074-02761988000500006
[40]
Kemp K, Theander TG, Hviid L, Garfar A, Kharazmi A, et al. (1999) Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol 49: 655–659. doi: 10.1046/j.1365-3083.1999.00554.x
[41]
Coutinho SG, Pirmez C, Da-Cruz AM (2002) Parasitological and immunological follow-up of American tegumentary leishmaniasis patients. Trans R Soc Trop Med Hyg 96: Suppl 1S173–S178. doi: 10.1016/S0035-9203(02)90072-6
[42]
Bomfim G, Andrade BB, Santos S, Clarencio J, Barral-Netto M, et al. (2007) Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. Am J Trop Med Hyg 77: 854–859.
[43]
Faria DR, Souza PE, Duraes FV, Carvalho EM, Gollob KJ, et al. (2009) Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol 31: 432–439. doi: 10.1111/j.1365-3024.2009.01125.x
[44]
Huber M, Timms E, Mak TW, Rollinghoff M, Lohoff M (1998) Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun 66: 3968–3970.
[45]
Belkaid Y, von SE, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992–4000.
[46]
Gaafar A, Veress B, Permin H, Kharazmi A, Theander TG, et al. (1999) Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol 91: 314–320. doi: 10.1006/clim.1999.4705
[47]
Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de JA, et al. (2002) Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70: 6734–6740. doi: 10.1128/IAI.70.12.6734-6740.2002
[48]
Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, et al. (2001) Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69: 3232–3239. doi: 10.1128/IAI.69.5.3232-3239.2001
[49]
Carvalho EM, Correia FD, Bacellar O, Almeida RP, Lessa H, et al. (1995) Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 53: 273–277.
[50]
Reis LC, Brito ME, Souza MA, Medeiros AC, Silva CJ, et al. (2009) Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment. J Clin Lab Anal 23: 63–69. doi: 10.1002/jcla.20291
